FDA Extends Comment Period for NDI Draft Guidance
Interested parties will now have until December 12, 2016 to submit comments on FDA’s revised new dietary ingredient (NDI) draft guidance-a 60-day extension over the previous deadline.
Photo by iStockphoto.com/ImageGap
FDA announced this morning it will be extending the public comment period for its revised new dietary ingredient (NDI) draft guidance. The extension announcement, which will be formally published in the Federal Register tomorrow, sets the new deadline for public comments as December 12, 2016-a 60-day extension over the previous deadline.
It’s been nearly two months since FDA released its revised NDI guidance, with industry reaction ranging from resistant to receptive. Several industry associations also requested an extension to the original deadline for public comment (October 17), including the American Herbal Products Association (Silver Spring, MD), the Natural Products Association (Washington, DC), the Council for Responsible Nutrition (Washington, DC), and the United Natural Products Alliance (Salt Lake City).
In its announcement, FDA says it is extending the comment period “in response to requests to extend the comment period to allow interested persons additional time to submit comments.”
Instructions for submitting comments can be found here.
Read more:
Is GRAS Still a Viable NDI Workaround?
How FDA’s NDI Guidance Could Paralyze Industry
Which Ingredient Categories Would Be Hit Hardest by FDA’s NDI Draft Guidance?
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
